Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
Karl L. Banta, Xiaozheng Xu, Avantika S. Chitre, Amelia Au‐Yeung, Chikara Takahashi, William O’Gorman, Thomas D. Wu, Stephanie Mittman, Rafael Cubas, Laëtitia Comps‐Agrar, Amit Fulzele, Eric J. Bennett, Jane L. Grogan, Enfu Hui, Eugene Y. Chiang, Ira Mellman
Abstract
T cell responses, requires blockade of TIGIT and PD-1, providing a mechanistic rationale for combinatorial targeting in the clinic.
Topics & Concepts
TIGITBlockadeCD28Cancer researchAtezolizumabCytotoxic T cellCD8T cellBiologyImmune checkpointReceptorImmune systemImmunotherapyImmunologyNivolumabBiochemistryIn vitroCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmune Cell Function and Interaction